Shots:
- Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs
- Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment
- Additionally, Pyxis get the license to Pfizer’s ADC platform that will expand its ADC portfolio and further strengthen its developmental capabilities
Click here to read full press release/ article | Ref: Businesswire | Image: PRNewswire
The post Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates first appeared on PharmaShots.
